Research programme: tuberculosis vaccine - Vaxil Biotherapeutics

Drug Profile

Research programme: tuberculosis vaccine - Vaxil Biotherapeutics

Alternative Names: MTbuVax

Latest Information Update: 25 Jan 2017

Price : $50

At a glance

  • Originator Vaxil BioTherapeutics
  • Class Peptides; Tuberculosis vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Tuberculosis

Most Recent Events

  • 19 Jan 2017 Vaxil Biotherapeutics receives patent allowance for MTbuVAX™ in USA
  • 27 Sep 2016 Tuberculosis vaccine is still in preclinical development for Tuberculosis in USA and Israel (Vaxil BioTherapeutics pipeline, September 2016)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Tuberculosis in Israel
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top